Trials
4 active
4 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy”In the company’s words, NCT06743126 on ClinicalTrials.gov
- Tested for
- Melanoma, Cutaneous Malignant, Mucosal Melanoma, Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer, Cutaneous Melanoma, Synovial Sarcoma
- Main trialPhase 3
- “This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma or mucosal melanoma (MM). For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/”In the company’s words, NCT06743126 on ClinicalTrials.gov
- Other names
- anzutresgene autoleucel · anzu-cel
Other drugs for Mucosal Melanoma
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- ISCIB1+Scancell Ltd · Phase 3
Coming up3
- Jan 2028Phase 3 trial completes · ClinicalTrials.gov
- Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
- Aug 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jan 2028 | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | |
| Phase 1/2Recruiting | Dec 2028 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | |
| Phase 1Recruiting | Aug 2029 | ACTengine® IMA203 Combined With mRNA-4203 | |
| Phase 1/2Authorised | not given | A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026